Employers Should Do Risk Analysis, Prepare Now for Ultra-High-Cost Therapies

Jul 17
Jul 17, 2025

Many ultra-high-cost cell and gene therapies come with the promise of a cure — but it’s not that simple. It’s unclear with many of the agents exactly how long that “cure” will last. And the process a person must go through both before and after treatment is an extensive one, necessitating coordination among various components. So while many employers may not have had a claim for one of these products, they still need to prepare for that possibility.

“These are not the typical therapies that we’ve seen in the past where you get a pill or you inject a drug, and you keep it at home, or you go to a location near your home and have the drug administered like a specialty drug for cancer or something,” explained Tom Sondergeld, managing partner at TS Consulting Group LLC, during a June 5 webinar from the Midwest Business Group on Health (MBGH). “This is much more advanced.”
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.